The placebo effect in early-phase glaucoma clinical trials

Current Eye Research

Volumn 40, Issue 6, 2015, Pages 653-656

  Sharpe, R Allan ^a   Nelson, Lindsay A ^b   Stewart, Jeanette A ^b   Stewart, William C ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b University of South Carolina   (United States)

Author keywords

Clinical studies; Glaucoma; Phase; Placebo effect

Indexed keywords

BETAXOLOL; BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; LEVOBUNOLOL; TIMOLOL; TRAVOPROST; UNOPROSTONE; ANTIHYPERTENSIVE AGENT;

CLINICAL TRIAL (TOPIC); GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRESSURE MEASUREMENT; PREVALENCE; PRIORITY JOURNAL; REVIEW; CIRCADIAN RHYTHM; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; CLINICAL TRIALS AS TOPIC; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE;

EID: 84928643270     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2014.946519     Document Type: Review

References (27)

1. Caldwell DR, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Arch Ophthalmol 1984;102:539-540.
2. Feghali JG, Kaufman PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a beta 1-adrenergic antagonist. Am J Ophthalmol 1985;100:777-782.
3. FDA Medical Review of Lumigan (Bimatoprost), Application 21-275, Protocol 192024-001. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2001/21275-Lumigan%200.03%20percent%20Opthalmis% 20Solution-medr-P2.pdf [last accessed 28 Jul 2014].
4. Laibovitz RA, VanDenburgh AM, Felix C, David R, Batoosingh A, Rosenthal A, Cheetham J. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol 2001; 119:994-1000.
5. FDA Medical Review of Lumigan (Bimatoprost), Application 21-275, Protocol 192024-003. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2001/21275-Lumigan%200.03%20percent%20Opthalmis% 20Solution-medr-P2.pdf [last accessed 28 Jul 2014].
6. FDA Medical Review of Lumigan (Bimatoprost), Application 21-275, Protocol 192024-004. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2001/21275-Lumigan%200.03%20percent%20Opthalmis% 20Solution-medr-P2.pdf [last accessed 28 Jul 2014].
7. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514-1517.
8. Derick RJ, Robin AL, Walters TR, Barnebey HS, Choplin N, Schuman J, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997;104:131-136.
9. FDA Medical Review of Brinzolamide (Azopt), Application 20-816, Protocol C92-25. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/20816-AZOPT-MEDR-P1.PDF [last accessed 28 Jul 2014].
10. Lippa EA, Schuman JS, Higginbotham EJ, Kass MA, Weinreb RN, Skuta GL, et al. MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991;98:308-312.
11. Lippa EA, Carlson LE, Ehinger B, Eriksson LO, Finnström K, Holmin C, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992;110:495-499.
12. Wilkerson M, Cyrlin M, Lippa EA, Esposito D, Deasy D, Panebianco D, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993;111: 1343-1350.
13. Rácz P, Ruzsonyi MR, Nagy ZT, Bito LZ. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study. Arch Ophthalmol 1993;111:657-661.
14. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100: 1297-1304.
15. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111:1351-1358.
16. Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 1993;100:1312-1316.
17. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 1993;100:1305-1311.
18. Villumsen J, Alm A. PhXA34-a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992;76: 214-217.
19. Partamian LG, Kass MA, Gordon M. A dose-response study of the effect of levobunolol on ocular hypertension. Am J Ophthalmol 1983;95:229-232.
20. Bensinger RE, Keates EU, Gofman JD, Novack GD, Levobunolol DE. A three-month efficacy study in the treatment of glaucoma and ocular hypertension. Arch Ophthalmol 1985;103:375-378.
21. Zimmerman TJ, Kaufman HE. Timolol: dose response and duration of action. Arch Ophthalmol 1977;95: 605-607.
22. FDA Medical Review of Travoprost (Travatan), Application 21-257, Protocol C-97-02. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/nda/2001/21257-Travatan-medr-P1.pdf [last accessed 28 Jul 2014].
23. FDA Medical Review of Unoprostone (Rescula), Application 21-214, Protocol C97-UIOS-003. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/21214-Rescula-medr-P2.pdf [last accessed 28 Jul 2014].
24. Kienle GS, Kiene H. The powerful placebo effect: fact or fiction? J Clin Epidemiol 1997;50:1311-1318.
25. Margo CE. The placebo effect. Surv Ophthalmol 1999;44: 31-44.
26. Haour F. Mechanisms of the placebo effect and of conditioning. Neuroimmunomodulation 2005;12:195-200.
27. Stewart WC. Clinical practice of glaucoma. Thorofare: SLACK Inc.; 1990. pp 255-297.